In a world-first international trial, adding a therapeutic cancer vaccine to standard immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%.
An international pooled study led by Professor Georgina Long AO, and published in Nature Medicine, showed patients whose tumours responded well to neoadjuvant immunotherapy had outstanding 5-year survival.
Read more about how researchers at Melanoma Institute Australia and The University of Sydney have led the way in showing that it’s not just the number of immune cells in a tumour that influences treatment response - it’s also where those cells are located and their type.
Over the next three months, Prof Georgina Long will work with some of Europe's leading cancer research and treatment centres, advancing collaborative research in melanoma and neoadjuvant immunotherapy.
Read more about how the MIA team continues to play a leading role in advancing the frontiers of melanoma research, presenting new findings at major international oncology conferences - the AACR Annual Meeting in San Diego, the EADO Congress in Prague, and ASCO in Chicago.
The Roadmap Annual Collaborators Meeting was hosted by MIA on 27 March 2026. Read more and view the Summary Report of the meeting.
Neoadjuvant immunotherapy continues to transform outcomes for people with melanoma and other cancers. Two recent papers show that assessing pathological response after neoadjuvant immunotherapy can be both more efficient and more consistent, without compromising accuracy.
Assoc Prof Inês da Silva, Medical Oncologist & Senior Researcher at MIA, was recently presented with the inaugural 'Marie Krogh Young Women in Science Prize' and the 'NSW Premier’s Awards Outstanding Mid-Career Researcher of the Year', in recognition of her groundbreaking contributions to melanoma treatment and care.
Leading Melanoma Institute Australia clinicians and researchers are in Europe to share latest research findings and clinical updates with international colleagues as we continue our efforts to reach zero deaths from melanoma.
Results of the RELATIVITY-098 clinical trial published in Nature Medicine show the presence of tumour is directly related to the effectiveness of combination immunotherapy for high risk and advanced melanoma, providing more evidence that neoadjuvant immunotherapy is the new frontier in treatment for melanoma, and other cancers.
